Elsevier

The Lancet

Volume 370, Issue 9588, 25–31 August 2007, Pages 636-637
The Lancet

Comment
Catecholamine treatment for shock—equally good or bad?

https://doi.org/10.1016/S0140-6736(07)61317-8Get rights and content

References (14)

  • M Lyte et al.

    Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes

    Lancet

    (2003)
  • RP Dellinger et al.

    Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

    Crit Care Med

    (2004)
  • D Annane et al.

    Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial

    Lancet

    (2007)
  • PP Freestone et al.

    Specificity of catecholamine-induced growth in Escherichia coli O157:H7, Salmonella enterica and Yersinia enterocolitica

    FEMS Microbiol Lett

    (2007)
  • PP Freestone et al.

    The mammalian neuroendocrine hormone norepinephrine supplies iron for bacterial growth in the presence of transferrin or lactoferrin

    J Bacteriol

    (2000)
  • R Oberbeck

    Catecholamines: physiological immunomodulators during health and illness

    Curr Med Chem

    (2006)
  • T van der Poll et al.

    Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-6 production in human whole blood

    Infect Immun

    (1994)
There are more references available in the full text version of this article.

Cited by (0)

View full text